Alan Wayne
Pediatric Hematology-Oncology · Los Angeles, CANPI 1841236171
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,640 of the $10,640 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Gilead.
Across 1 payment — averaging $10,640 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
Across 50 payments — averaging $76,506 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.7M
- Amgen$1.4M
- Gilead$598K
- Novartis$59K
- Aurobindo Pharma USA, Inc.$43K
- Acrotech Biopharma Inc.$34K
- plus $13K from 1 others
What the payments were for
- Consulting fees$10,640100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $10,640 |
How this compares
$10,640 in reported general payments places this provider in the 75th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Los Angeles
- Noah FedermanLos Angeles$399K
- Jan van TornoutLos Angeles$137K
- Thomas CoatesLos Angeles$99K
- Andrew DietzLos Angeles$88K
- Geetha PuthenveetilLos Angeles$62K
- Hisham Abdel AzimLos Angeles$52K
- Michael PulsipherLos Angeles$45K
- Leo MascarenhasLos Angeles$35K
- Edward GompertsLos Angeles$28K
- Paibel Aguayo-HiraldoLos Angeles$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.